ClinConnect ClinConnect Logo
Search / Trial NCT06967467

Allergy Delabeling in Antibiotic Stewardship - Evaluations

Launched by UNIVERSITY OF PENNSYLVANIA · May 2, 2025

Trial Information

Current as of July 27, 2025

Not yet recruiting

Keywords

Penicillin Allergy Hematologic Cancer Allergy Delabeling

ClinConnect Summary

The RENEW-EVAL clinical trial is focused on understanding the challenges of introducing a new approach to managing patients with a specific allergy to beta-lactam antibiotics, which are commonly used to treat infections. This study is particularly looking at patients who have blood cancers, such as lymphoma, leukemia, or myeloma, and who currently have a record indicating they are allergic to these antibiotics. The researchers want to find out how to better integrate this new approach into everyday medical care for these patients.

To be eligible for the trial, patients must be hospitalized for their cancer treatment and have a documented allergy to beta-lactam antibiotics. The study is not currently open for recruitment, but it aims to include adult patients aged 65 to 74, along with their healthcare providers. Participants will share their experiences and insights during the study, which will help improve future care for patients with blood cancers. It’s important to note that not everyone will qualify for the study, as certain medical conditions could exclude potential participants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient participants:
  • a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
  • a prior label applied to their medical record to indicate a beta lactam allergy
  • hospitalized as an inpatient to an oncology service at the time the study is conducted
  • Clinician participants:
  • member of the primary inpatient care team
  • Exclusion Criteria:
  • Patient participants:
  • meet one of the exclusionary criteria for the RENEW clinical intervention
  • Clinician participants:
  • no exclusions

About University Of Pennsylvania

The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported